Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Symbiotec Pharmalab / Equity Capital Markets

<ul>
<li>Symbiotec Pharmalab will launch its India IPO on August 24. The IPO consists of fresh issue of INR1.5B and OFS of INR16.1B. The price band is set at INR938–988.</li>
<li>The IPO subscription will close on August 27, with expected listing on September 1. At the upper price band, the company is seeking a market cap of INR62B (~$650M).</li>
<li>The company proposes to deploy an estimated amount of INR1B in FY27 for repayment of borrowings. As of March 31, 2026, total outstanding borrowings stood at INR3.9B.</li>
</ul>


Symbiotec Pharmalab will launch its India IPO on August 24. The IPO consists of fresh issue of INR1.5B and OFS of INR16.1B. The price band is set at INR938–988.
The IPO subscription will close on August 27, with expected listing on September 1. At the upper price band, the company is seeking a market cap of INR62B (~$650M).
The company proposes to deploy an estimated amount of INR1B in FY27 for repayment of borrowings. As of March 31, 2026, total outstanding borrowings stood at INR3.9B.


Symbiotec Pharmalab IPO: Global Leadership in Niche APIs to Support Sustainable Growth

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Juniper Green Energy Ltd / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/juniper-green-energy-ltd" target="_blank" data-smartkarma-citation="entities:45455:1" rel="noopener">Juniper Green Energy Ltd (1831458D IN) </a>raised about US$187m in its India IPO.</li>
<li>Juniper Green Energy Limited (JGEL) is an independent power producer (IPP) engaged in the development, construction, operation, and maintenance of utility-scale renewable energy projects.</li>
<li>We have looked at the past performance and valuations in our previous note. In this note, we talk about the trading dynamics.</li>
</ul>



Juniper Green Energy Ltd (1831458D IN) raised about US$187m in its India IPO.
Juniper Green Energy Limited (JGEL) is an independent power producer (IPP) engaged in the development, construction, operation, and maintenance of utility-scale renewable energy projects.
We have looked at the past performance and valuations in our previous note. In this note, we talk about the trading dynamics.


Aequitas: Juniper Green Energy IPO Trading - Subdued Demand

Chief Executive Officer, Emmer Capital Partners Limited

Manishi Raychaudhuri

Chief Executive Officer

Emmer Capital Partners Limited

Emmer Capital Partners is an Asia Pacific focused financial advisory firm engaging in strategic financial asset allocation advice, bespoke thematic research and advising early-stage companies and connecting them to investors. Emmer Capital provides macro-economic and multi-asset investment strategy inputs to institutions, family offices, private wealth managers, private equity, and corporate boards directly and through independent research platforms. Emmer Capital also advises a wide range of startup companies on fund raising and business strategy. Emmer Capital's active engagement with the print and electronic media reaches a broad spectrum of investors across the globe.

Equity Bottom-Up

<ul>
<li>India's Nifty50 index reached an all-time high yesterday. However, many Indian stocks are near their 52-week lows. Many among them have strong forecast earnings growth, good balance sheets, attractive valuations.</li>
<li>We screen 17 stocks with double digit forecast EPS growth, PEG &lt; 1.4x, net debt to equity less than 50%. They are spread across construction, chemicals, healthcare, industrials and technology.</li>
<li>The largest five are <a href="https://www.smartkarma.com/entities/deepak-nitrite-ltd" target="_blank" data-smartkarma-citation="entities:5845" rel="noopener">Deepak Nitrite (DN IN)</a>, <a href="https://www.smartkarma.com/entities/cohance-lifesciences-limited" target="_blank" data-smartkarma-citation="entities:33463" rel="noopener">Cohance Lifesciences (COHANCE IN)</a>, <a href="https://www.smartkarma.com/entities/basf-india-ltd" target="_blank" data-smartkarma-citation="entities:19253" rel="noopener">BASF India Ltd (BASF IN)</a>, <a href="https://www.smartkarma.com/entities/crompton-greaves-consumer-electricals" target="_blank" data-smartkarma-citation="entities:24046" rel="noopener">Crompton Greaves Consumer Electricals (CROMPTON IN)</a>, <a href="https://www.smartkarma.com/entities/clean-science-and-technology" target="_blank" data-smartkarma-citation="entities:33648" rel="noopener">Clean Science and Technology (CLEAN IN)</a>.</li>
</ul>


India's Nifty50 index reached an all-time high yesterday. However, many Indian stocks are near their 52-week lows. Many among them have strong forecast earnings growth, good balance sheets, attractive valuations.
We screen 17 stocks with double digit forecast EPS growth, PEG &lt; 1.4x, net debt to equity less than 50%. They are spread across construction, chemicals, healthcare, industrials and technology.
The largest five are Deepak Nitrite (DN IN), Cohance Lifesciences (COHANCE IN), BASF India Ltd (BASF IN), Crompton Greaves Consumer Electricals (CROMPTON IN), Clean Science and Technology (CLEAN IN).


Asian Equities: India's Nifty Is at All-Time High, These Quality Stocks Are Not.

Equity Analyst - Fundamental & Thematic, Sree Capital

Sreemant Dudhoria

Equity Analyst - Fundamental & Thematic

Fundamental Research on Listed Indian Companies

Sree Capital

Sree Capital is a platform to share fundamental research on listed Indian companies. We do this research for our own investment

<ul>
<li>
 Strong Revenue Momentum and Profitability:<a href="https://www.smartkarma.com/entities/anthem-biosciences" target="_blank" data-smartkarma-citation="entities:44206:1" rel="noopener">Anthem Biosciences (1234D IN)</a> achieved INR 18.4bn in revenue in FY25, growing 25% CAGR over FY20–FY25,with industry-leading EBITDA margins of 36.8% and PAT margin of 23.4%</li>
<li>
 Unique Dual Capability in Biologics and Small Molecules:Among the few Indian CRDMOs with end-to-end capabilities across both small and large molecules, and technology-driven portfolio including ADCs, RNAi, peptides, and oligonucleotides</li>
<li>
 Peer-Leading Returns and Robust Pipeline: Anthem boasts the highest ROCE (26.9%) among Indian peers, with significant IP-backed revenue streams and global molecule commercialization. It is a BUY for long term.</li>
</ul>



 Strong Revenue Momentum and Profitability:Anthem Biosciences (1234D IN) achieved INR 18.4bn in revenue in FY25, growing 25% CAGR over FY20–FY25,with industry-leading EBITDA margins of 36.8% and PAT margin of 23.4%

 Unique Dual Capability in Biologics and Small Molecules:Among the few Indian CRDMOs with end-to-end capabilities across both small and large molecules, and technology-driven portfolio including ADCs, RNAi, peptides, and oligonucleotides

 Peer-Leading Returns and Robust Pipeline: Anthem boasts the highest ROCE (26.9%) among Indian peers, with significant IP-backed revenue streams and global molecule commercialization. It is a BUY for long term.


Anthem Biosciences IPO: Despite 100% OFS, Worth Accumulating for Long-Term Compounding

Anthem Biosciences / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/anthem-biosciences" target="_blank" data-smartkarma-citation="entities:44206:1" rel="noopener"></a>Anthem Biosciences has filed RHP to raise INR34B (~$395M) through its Indian IPO consisting of only an offer for sale of equity shares. The IPO will open on July 14.</li>
<li>The IPO has been priced at INR540–570 per share. Considering FY25 EPS of INR8.07, Anthem seeks P/E valuation of 66.9–70.6x, which is lower than most of the peers.</li>
<li>With niche and differentiated technical capabilities (ADC, biosimilars, innovative biologics etc), large clientele, exposure to commercialized molecules, and capacity expansion, Anthem is well-positioned for long-term growth.</li>
</ul>



Anthem Biosciences has filed RHP to raise INR34B (~$395M) through its Indian IPO consisting of only an offer for sale of equity shares. The IPO will open on July 14.
The IPO has been priced at INR540–570 per share. Considering FY25 EPS of INR8.07, Anthem seeks P/E valuation of 66.9–70.6x, which is lower than most of the peers.
With niche and differentiated technical capabilities (ADC, biosimilars, innovative biologics etc), large clientele, exposure to commercialized molecules, and capacity expansion, Anthem is well-positioned for long-term growth.


Anthem Biosciences IPO: FY25 In High Trajectory; Poised for Long-Term Growth; Attractive IPO Pricing

India

Cohance Lifesciences operates as a global Contract Development and Manufacturing Organization (CDMO) and API platform, providing services for small molecule APIs, advanced intermediates, and finished dosage forms. The company offers integrated solutions from early-stage development to commercial-scale manufacturing for pharmaceutical, biotechnology, and chemical companies. Cohance Lifesciences is headquartered in Hyderabad, India, and was founded in 2018.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cohance Lifesciences (COHANCE IN)

Symbiotec Pharmalab IPO: Global Leadership in Niche APIs to Support Sustainable Growth

Symbiotec Pharmalab launches India IPO consisting of fresh issue of INR2B and OFS of INR16B. The price band is set at INR938–988. The IPO proceeds...

Tina Banerjee

Aequitas: Juniper Green Energy IPO Trading - Subdued Demand

Juniper Green Energy Ltd (JGEL) raised about US$187m in its India IPO. In this note, we talk about the demand and the trading dynamics.

Akshat Shah

Asian Equities: India's Nifty Is at All-Time High, These Quality Stocks Are Not.

India's Nifty50 hit its all-time high while many stocks are near 52-week lows. We identify 17 stocks with strong earnings growth, good balance...

Manishi Raychaudhuri

Anthem Biosciences IPO: Despite 100% OFS, Worth Accumulating for Long-Term Compounding

Anthem Biosciences' strong revenue growth, industry-leading profitability, unique dual capability in biologics and small molecules, & peer-leading...

Sreemant Dudhoria

Anthem Biosciences IPO: FY25 In High Trajectory; Poised for Long-Term Growth; Attractive IPO Pricing

Anthem Biosciences’ INR34B ($395M) India IPO consisting of only OFS will open for subscription on July 14. The IPO has been priced at INR540–570...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Symbiotec Pharmalab IPO: Global Leadership in Niche APIs to Support Sustainable Growth

Symbiotec Pharmalab launches India IPO consisting of fresh issue of INR2B and OFS of INR16B. The price band is set at INR938–988. The IPO proceeds...

Tina Banerjee

Aequitas: Juniper Green Energy IPO Trading - Subdued Demand

Juniper Green Energy Ltd (JGEL) raised about US$187m in its India IPO. In this note, we talk about the demand and the trading dynamics.

Akshat Shah

Asian Equities: India's Nifty Is at All-Time High, These Quality Stocks Are Not.

​India's Nifty50 hit its all-time high while many stocks are near 52-week lows. We identify 17 stocks with strong earnings growth, good balance...

Manishi Raychaudhuri

Anthem Biosciences IPO: Despite 100% OFS, Worth Accumulating for Long-Term Compounding

​Anthem Biosciences' strong revenue growth, industry-leading profitability, unique dual capability in biologics and small molecules, & peer-leading...

Sreemant Dudhoria

Anthem Biosciences IPO: FY25 In High Trajectory; Poised for Long-Term Growth; Attractive IPO Pricing

Anthem Biosciences’ INR34B ($395M) India IPO consisting of only OFS will open for subscription on July 14. The IPO has been priced at INR540–570...

Tina Banerjee

India's Nifty50 hit its all-time high while many stocks are near 52-week lows. We identify 17 stocks with strong earnings growth, good balance...

Anthem Biosciences' strong revenue growth, industry-leading profitability, unique dual capability in biologics and small molecules, & peer-leading...